Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator

Department of Medicine, University of Florida College of Medicine, Gainesville.

Coronary artery reocclusion after thrombolysis with human recombinant tissue-type plasminogen activator (rt-PA) is related to the short half-life of this agent in plasma. K2P, a mutant of rt-PA lacking the fibronectin fingerlike, epidermal growth factor-like and first kringle domains (amino acids 6 to 173) and having the glycosylation site Asn184 mutagenized to Gln, has been produced in Chinese hamster ovary cells. In this study we compared the thrombolytic effect of K2P and rt-PA in dogs with electrically induced coronary artery thrombosis. Both agents were given intravenously in equimolar amounts over 20 min after the occlusive thrombus was stable for 30 min; dogs were monitored for 1 h after reperfusion if flow occurred. Coronary blood flow was restored by rt-PA in 6 (60%) of 10 dogs. The restored flow lasted for 49 +/- 12 min and mean flow at 60 min from the start of reperfusion was 7 +/- 3 ml/min. The reocclusion rate was 50% (three of six dogs). Flow was restored in five (100%) of five dogs by K2P. The restored blood flow lasted during the entire 1-h observation period in all but one dog and mean flow at 60 min was 49 +/- 16 ml/min (p less than 0.02 vs. flow in rt-PA-treated dogs). Restored coronary blood flow showed marked cyclic flow variations in rt-PA-treated but not in K2P-treated dogs.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J. T. Willerson Myocardial Revascularization with Cardiologic Interventional Devices Card. Surg. Adult, January 1, 2003; 2(2003): 561 - 580. [Full Text]

				D. Li, S. Weng, B. Yang, D. S. Zander, T. Saldeen, W. W. Nichols, S. Khan, and J. L. Mehta Inhibition of Arterial Thrombus Formation by ApoA1 Milano Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 378 - 383. [Abstract] [Full Text] [PDF]

				K. Fujise, B. M. Revelle, L. Stacy, E. L. Madison, E. T.H. Yeh, J. T. Willerson, and P. J. Beck A Tissue Plasminogen Activator/P-Selectin Fusion Protein Is an Effective Thrombolytic Agent Circulation, February 4, 1997; 95(3): 715 - 722. [Abstract] [Full Text]

				M. J. Silver, J. M. Sutton, S. Hook, P. Lee, J. L. Malycky, M. L. Phillips, S. G. Ellis, E. J. Topol, and F. A. Nicolini Adjunctive Selectin Blockade Successfully Reduces Infarct Size Beyond Thrombolysis in the Electrolytic Canine Coronary Artery Model Circulation, August 1, 1995; 92(3): 492 - 499. [Abstract] [Full Text]